Business Overview / Sources of Revenue

**Hims & Hers Health (NYSE: HIMS)** is a telehealth platform founded in 2017, offering personalized treatments for men's and women's health issues like sexual health, hair loss, dermatology, mental health, weight management, and personal care products via online consultations with licensed providers.[1][2]

Customers access prescriptions (fulfilled by partner pharmacies) and over-the-counter items (e.g., skincare, supplements) on a subscription basis for recurring delivery, generating predictable revenue through direct-to-consumer sales and retail partnerships.[1][2]

No specific percentage breakdown of revenue sources (e.g., subscriptions vs. one-time) is detailed in available data; core model relies on consultations, meds, and products.[1][2]

Revenue Growth Potential and Recurrence

Hims & Hers generates a **very high share of recurring revenue**: over **90% of sales come from subscriptions**, according to investor materials and independent analysis.[4] This is supported by 2.2–2.5 million subscribers and rising monthly revenue per subscriber (up 19% in 2024).[2][4]

Revenue growth has been exceptional: **+69% in 2024** to about **$1.5 billion**, with 2025 guidance of **$2.3–2.4 billion** (roughly **+55–60%**).[2][5] Q3 2025 revenue grew **49% year over year**.[1][6]

Looking 5+ years out, consensus expects growth to slow but remain strong, with analysts modeling roughly **20%+ annual revenue growth** near term after this explosive phase.[3] Key drivers are GLP‑1 weight loss, increasing ARPU, and expansion into new specialties, though marketing intensity and competition could moderate growth.

Economic Moat Factors

Hims & Hers likely has at most a **narrow moat**, and it is still developing.

• **Brand**: Its primary edge is a strong, consumer-facing brand in telehealth, with high retention and trust around sensitive issues (sexual health, hair loss, GLP‑1 weight loss).[1][2][4][5]

• **Scale / cost**: Growing volume, in‑house manufacturing, and large marketing reach create some scale-driven cost advantages that Hims partially passes on via lower prices.[1][4]

• **Switching costs & network effects**: Switching costs are low and there is little true network effect; patients can move easily to other telehealth or traditional providers.[1][2][7]

• **Uniqueness**: Most offerings are not proprietary; larger incumbents could replicate products and distribution.[1][2][7]

Overall, modest brand and scale advantages exist, but entry barriers remain limited.

Leadership

Hims & Hers is led by **co‑founder/CEO Andrew Dudum**, who has served as CEO and director since **September 2016**.[5] He helped launch Hims within Atomic Labs and has led it from inception through its 2021 SPAC listing.[1][3][4][5] Public filings show Dudum as a **significant shareholder**; as founder‑CEO he holds a multi‑percent ownership stake, giving him strong economic alignment with investors (exact percentage fluctuates with stock/awards). The broader team includes experienced leaders such as Chief Medical Officer **Dr. Patrick Carroll**, overseeing clinical quality and safety.[5]

Financial Health

Hims & Hers has a **very strong balance sheet**, with over **$1.5B in cash and short-term investments and no debt**, giving it ample financial flexibility.[7][6] The business is **free-cash-flow positive**; management highlights strong cash generation, with free cash flow running at a **high-single- to low‑double‑digit percentage of revenue** (i.e., roughly a 8–12% free cash flow margin).[4][7] The company historically issued shares to fund growth, but in 2025 it authorized a **$250M share repurchase program**, signaling a shift away from net dilution toward **net repurchases**.[6]

Last updated Dec 14, 2025